ALLO vs. CDTX, PRAX, ELVN, AVDL, ARDX, DYN, GPCR, BGM, GHRS, and AKBA
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Cidara Therapeutics (CDTX), Praxis Precision Medicines (PRAX), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), BGM Group (BGM), GH Research (GHRS), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs. Its Competitors
Allogene Therapeutics (NASDAQ:ALLO) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.
Allogene Therapeutics' return on equity of -52.98% beat Cidara Therapeutics' return on equity.
Allogene Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 3.9% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Allogene Therapeutics currently has a consensus target price of $8.44, indicating a potential upside of 464.85%. Cidara Therapeutics has a consensus target price of $57.29, indicating a potential downside of 6.36%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Cidara Therapeutics.
Cidara Therapeutics has higher revenue and earnings than Allogene Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cidara Therapeutics had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Cidara Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.96 beat Cidara Therapeutics' score of 0.42 indicating that Allogene Therapeutics is being referred to more favorably in the media.
Summary
Allogene Therapeutics beats Cidara Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 7/25/2025 by MarketBeat.com Staff
Free ALLO Stock Alerts